UA49789C2 - Use of dimerised form of lysozyme for manufacture of medicament for inhibiting biosynthesis of tumor necrosis factor in animals and humans, method for prevention and treatment of diseases (variants), pharmaceutical formulations (variants), use of dimerised form of lysozyme for aids prevention and treatment - Google Patents
Use of dimerised form of lysozyme for manufacture of medicament for inhibiting biosynthesis of tumor necrosis factor in animals and humans, method for prevention and treatment of diseases (variants), pharmaceutical formulations (variants), use of dimerised form of lysozyme for aids prevention and treatmentInfo
- Publication number
- UA49789C2 UA49789C2 UA95018021A UA95018021A UA49789C2 UA 49789 C2 UA49789 C2 UA 49789C2 UA 95018021 A UA95018021 A UA 95018021A UA 95018021 A UA95018021 A UA 95018021A UA 49789 C2 UA49789 C2 UA 49789C2
- Authority
- UA
- Ukraine
- Prior art keywords
- lysozyme
- treatment
- variants
- prevention
- necrosis factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Materials Engineering (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Винахід стосується застосування димеризованої форми лізоциму для виробництва фармакологічного засобу, який інгібує біосинтез фактора некрозу пухлин людини та тварин. Димер лізоциму, зокрема, може знайти своє застосування для лікування і профілактики захворювань, пов’язаних із надмірними рівнями фактора некрозу пухлин в організмі. Винахід також стосується лікарських форм препаратів, зокрема, призначених для ін’єкцій, які містять димеризовану форму лізоциму в кількості 0,01-10 мг/мл у вигляді стерильного апірогенного розчину, до складу якого входять фізіологічно прийнятний розчинник та фармацевтично апробований консервант. У винаході розглядаються також лікарські форми у вигляді тампонів та антисептичних пов’язок, імпрегнованих розчином, що містить димер лізоциму, а також лікарські форми у вигляді мазей та гелів, які містять ефективну дозу димеризованої форми лізоциму. Запропоновані засоби призначаються для профілактики та/або лікування сепсису та септичного шоку, особливо у випадку інфікованих ран.The invention relates to the use of a dimerized form of lysozyme for the production of a pharmacological agent that inhibits the biosynthesis of necrosis factor of human and animal tumors. Lysozyme dimer, in particular, can be used to treat and prevent diseases associated with excessive levels of tumor necrosis factor in the body. The invention also relates to dosage forms, in particular for injection, which contain a dimerized form of lysozyme in the amount of 0.01-10 mg / ml in the form of a sterile pyrogen-free solution, which includes a physiologically acceptable solvent and a pharmaceutically approved preservative. The invention also contemplates dosage forms in the form of tampons and antiseptic dressings impregnated with a solution containing a lysozyme dimer, as well as dosage forms in the form of ointments and gels containing an effective dose of a dimerized form of lysozyme. The proposed means are intended for the prevention and / or treatment of sepsis and septic shock, especially in the case of infected wounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL92295273A PL173978B1 (en) | 1992-07-13 | 1992-07-13 | Method of obtaining a preparation capable to retard the synthesis of endogenous cytotoxic cytokinins |
| PCT/EP1993/001841 WO1994001127A1 (en) | 1992-07-13 | 1993-07-13 | Lysozyme dimer and compositions containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA49789C2 true UA49789C2 (en) | 2002-10-15 |
Family
ID=20058087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA95018021A UA49789C2 (en) | 1992-07-13 | 1993-07-13 | Use of dimerised form of lysozyme for manufacture of medicament for inhibiting biosynthesis of tumor necrosis factor in animals and humans, method for prevention and treatment of diseases (variants), pharmaceutical formulations (variants), use of dimerised form of lysozyme for aids prevention and treatment |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6132715A (en) |
| EP (1) | EP0651654B1 (en) |
| JP (1) | JPH07508744A (en) |
| KR (1) | KR100289841B1 (en) |
| CN (1) | CN1057937C (en) |
| AT (1) | ATE252392T1 (en) |
| AU (1) | AU677786B2 (en) |
| BG (1) | BG63331B1 (en) |
| BR (1) | BR9306722A (en) |
| CA (1) | CA2140140A1 (en) |
| CZ (1) | CZ286725B6 (en) |
| DE (2) | DE69333258T2 (en) |
| DK (1) | DK0651654T3 (en) |
| ES (1) | ES2074037T3 (en) |
| FI (1) | FI950144L (en) |
| GE (1) | GEP20012466B (en) |
| GR (1) | GR950300039T1 (en) |
| HU (1) | HU218151B (en) |
| MX (1) | MX9304197A (en) |
| NZ (2) | NZ254135A (en) |
| OA (1) | OA10125A (en) |
| PL (1) | PL173978B1 (en) |
| PT (1) | PT651654E (en) |
| RO (1) | RO112580B1 (en) |
| RU (1) | RU2145875C1 (en) |
| SG (1) | SG52727A1 (en) |
| SK (1) | SK282377B6 (en) |
| TW (1) | TW259710B (en) |
| UA (1) | UA49789C2 (en) |
| WO (1) | WO1994001127A1 (en) |
| ZA (1) | ZA935046B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6183742B1 (en) | 1992-07-13 | 2001-02-06 | Nika Health Products, Limited | Applications of lysozyme dimer |
| DZ1964A1 (en) * | 1995-01-13 | 2002-10-15 | Nika Health Products Ltd | New applications of a lysozyme dimer. |
| WO1996038115A1 (en) * | 1995-05-30 | 1996-12-05 | Lectin Biopharma, Inc. | Method of using lectins for agglutination and collection of menstrual flow |
| US6123937A (en) * | 1997-03-14 | 2000-09-26 | Nika Health Products, Limited | Applications of lysozyme dimer |
| ITMI981148A1 (en) | 1998-05-22 | 1999-11-22 | Therapicon Srl | USE OF MODIFIED LYSOZYME C TO PREPARE MEDICINE COMPOSITIONS FOR THE TREATMENT OF SOME SERIOUS DISEASES |
| EP1174147A1 (en) * | 2000-06-27 | 2002-01-23 | Nika Health Products Limited | Reversal of antibiotic resistance with lysozyme dimer |
| US20050244402A1 (en) * | 2004-04-30 | 2005-11-03 | Villanueva Julie M | Absorption of pain-causing agents |
| RU2320367C1 (en) * | 2006-08-22 | 2008-03-27 | Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию (ГОУ ДПО РМАПО Росздрава) | Method for accompanying treatment of lymphoblast leucosis |
| RU2351351C1 (en) * | 2007-08-08 | 2009-04-10 | Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) | Medication increasing non-specific resistance of organism to bacterial endotoxins |
| RU2472467C2 (en) * | 2011-04-13 | 2013-01-20 | Государственное научное учреждение Краснодарский научно-исследовательский ветеринарный институт (ГНУ КНИВИ) | Method of preventing and treating gastroenteritis, caused by bacteriosis, in calves |
| CN105106626A (en) * | 2015-09-30 | 2015-12-02 | 成都倍加特生物科技有限公司 | Decoction medicine for treating menstrual period infection and preparation method of decoction medicine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR4020M (en) * | 1965-01-29 | 1966-03-21 | ||
| FR2215201A1 (en) * | 1973-01-24 | 1974-08-23 | Theranol Lab | Broad-spectrum antibiotic compsns. - contg. antibiotic resistant lactic bacilli and enzyme diffusing-agent |
| JPS5533408A (en) * | 1978-08-30 | 1980-03-08 | Eisai Co Ltd | Immunity-increasing agent |
| JPS5533409A (en) * | 1978-08-30 | 1980-03-08 | Eisai Co Ltd | Carcinostatic agent |
| JPS5543040A (en) * | 1978-09-25 | 1980-03-26 | Eisai Co Ltd | Immunity raising agent |
| US4221794A (en) * | 1979-06-21 | 1980-09-09 | Newport Pharmaceuticals International, Inc. | Method of imparting immunomodulating and antiviral activity |
| US4457919A (en) * | 1980-03-14 | 1984-07-03 | Newport Pharmaceutical International, Inc. | Method of imparting immunomodulating, antiviral or antitumor activity |
| US4510144A (en) * | 1981-08-26 | 1985-04-09 | Newport Pharmaceuticals International | Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives |
| US4739046A (en) * | 1985-08-19 | 1988-04-19 | Luzio Nicholas R Di | Soluble phosphorylated glucan |
| US4744984A (en) * | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
| DE3782958D1 (en) * | 1986-02-19 | 1993-01-21 | Imreg Inc | METHOD AND MEANS FOR TESTING AN IMMUNE SYSTEM. |
| US5200182A (en) * | 1988-05-26 | 1993-04-06 | Nika Health Products, Ltd. | Antiviral or antibacterial composition and method of use |
| DE3817955A1 (en) * | 1988-05-27 | 1989-11-30 | Hoechst Ag | MEDICINAL PRODUCT CONTAINING TNF INHIBITOR |
| ATE148565T1 (en) * | 1988-05-31 | 1997-02-15 | Napp Systems Inc | DEVICE AND METHOD FOR TREATING PRINTING PLATES |
| AU6355190A (en) * | 1989-06-13 | 1991-01-17 | Smithkline Beecham Corporation | Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages |
| HK1007456A1 (en) * | 1990-01-08 | 1999-04-09 | Nika Health Products Limited | Method of preparing lysozyme dimers |
| US5314816A (en) * | 1990-01-08 | 1994-05-24 | Nika Health Products Ltd. | Method of preparing lysozyme dimers |
| JPH06500078A (en) * | 1990-08-03 | 1994-01-06 | スミスクライン・ビーチャム・コーポレイション | TNF inhibitor |
-
1992
- 1992-07-13 PL PL92295273A patent/PL173978B1/en not_active IP Right Cessation
-
1993
- 1993-07-13 MX MX9304197A patent/MX9304197A/en not_active IP Right Cessation
- 1993-07-13 SK SK40-95A patent/SK282377B6/en not_active IP Right Cessation
- 1993-07-13 NZ NZ254135A patent/NZ254135A/en not_active IP Right Cessation
- 1993-07-13 UA UA95018021A patent/UA49789C2/en unknown
- 1993-07-13 DE DE69333258T patent/DE69333258T2/en not_active Expired - Lifetime
- 1993-07-13 DK DK93915903T patent/DK0651654T3/en active
- 1993-07-13 RU RU95105517A patent/RU2145875C1/en not_active IP Right Cessation
- 1993-07-13 ES ES93915903T patent/ES2074037T3/en not_active Expired - Lifetime
- 1993-07-13 AU AU45686/93A patent/AU677786B2/en not_active Ceased
- 1993-07-13 KR KR1019940704649A patent/KR100289841B1/en not_active Expired - Fee Related
- 1993-07-13 EP EP93915903A patent/EP0651654B1/en not_active Expired - Lifetime
- 1993-07-13 WO PCT/EP1993/001841 patent/WO1994001127A1/en not_active Ceased
- 1993-07-13 FI FI950144A patent/FI950144L/en unknown
- 1993-07-13 CA CA002140140A patent/CA2140140A1/en not_active Abandoned
- 1993-07-13 RO RO95-00041A patent/RO112580B1/en unknown
- 1993-07-13 BR BR9306722A patent/BR9306722A/en not_active Application Discontinuation
- 1993-07-13 CZ CZ199585A patent/CZ286725B6/en not_active IP Right Cessation
- 1993-07-13 HU HU9500098A patent/HU218151B/en not_active IP Right Cessation
- 1993-07-13 AT AT93915903T patent/ATE252392T1/en not_active IP Right Cessation
- 1993-07-13 SG SG1996008336A patent/SG52727A1/en unknown
- 1993-07-13 PT PT93915903T patent/PT651654E/en unknown
- 1993-07-13 GE GEAP19932466A patent/GEP20012466B/en unknown
- 1993-07-13 JP JP6502985A patent/JPH07508744A/en active Pending
- 1993-07-13 DE DE0651654T patent/DE651654T1/en active Pending
- 1993-07-13 ZA ZA935046A patent/ZA935046B/en unknown
- 1993-07-13 CN CN93116771A patent/CN1057937C/en not_active Expired - Fee Related
- 1993-08-03 TW TW082106180A patent/TW259710B/zh active
-
1994
- 1994-12-22 BG BG99287A patent/BG63331B1/en unknown
-
1995
- 1995-01-13 OA OA60604A patent/OA10125A/en unknown
- 1995-06-07 US US08/476,561 patent/US6132715A/en not_active Expired - Fee Related
- 1995-07-31 GR GR950300039T patent/GR950300039T1/en unknown
-
1996
- 1996-09-13 NZ NZ299377A patent/NZ299377A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200000468A1 (en) | THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY | |
| IL139231A0 (en) | Preparations for the application of anti-inflammatory, especially antiseptic, agents and/or agents promoting the healing of wounds to the lower respiratory tract | |
| ES2194392T3 (en) | ALFA-AMINOAMIDIC DERIVATIVES USED AS ANALGESIC AGENTS. | |
| CY1116463T1 (en) | Combination therapy for the therapeutic treatment of Protein Deficiency Disorders | |
| ATE375341T1 (en) | THIADIAZOLYLPIPERAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OR PREVENTION OF PAIN | |
| EA199900499A1 (en) | PHARMACEUTICAL COMPOSITION, INCLUDING A COMPOUND, OWNED ANTI-XA ACTIVITY, AND CONNECTION ANTAGONIST OF PLATELET AGGREGATION | |
| ATE209908T1 (en) | RADICAL CAPTURER (ßSPIN TRAPSß) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATION OF LIPIDS AND PROTEINS | |
| Santschi et al. | How to perform equine intravenous digital perfusion | |
| CY1110078T1 (en) | INJECTIONS WITH IODIDATED POVIDON FOR WASTE HEALING | |
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| UA35567C2 (en) | Pharmaceutical preparation for treating patients with coagulation impairment, method for treatment, method for pharmaceutical manufacturing | |
| UA49789C2 (en) | Use of dimerised form of lysozyme for manufacture of medicament for inhibiting biosynthesis of tumor necrosis factor in animals and humans, method for prevention and treatment of diseases (variants), pharmaceutical formulations (variants), use of dimerised form of lysozyme for aids prevention and treatment | |
| RU95106821A (en) | Cyclopeptides, method of their synthesis, pharmaceutical composition and method of its preparing | |
| WO1991002529A2 (en) | Product and method for killing abnormal vertebrate cells | |
| DE60018409D1 (en) | USE OF ANTISEPTICA FOR THE PREPARATION OF MEDICAMENTS FOR THE PROPHYLAXIS AND THE TREATMENT OF INFECTIONS AND / OR FUNCTIONAL TISSUE FORMATIONS IN THE BODY'S INSECTS | |
| MX9805441A (en) | Therapeutic compounds. | |
| AU5643299A (en) | Humic acid and its use in the treatment of various conditions | |
| RU95105517A (en) | APPLICATION OF THE DYMER OF LYSOZYME AS A MEDICINAL PRODUCT AND CONTAINING ITS COMPOSITIONS | |
| US4474759A (en) | Method of treating bacterial, viral or parasitic diseases | |
| ATE302011T1 (en) | PONAZURIL FOR THE TREATMENT OF DISEASES CAUSED BY COCCIDIA NEUROLOGICAL AND ABORTIGENICS | |
| KR927002224A (en) | Antitumor Enhancers and Antitumor Agents | |
| EA200400348A1 (en) | CYPLATINE COMPOSITIONS OF REDUCED TOXICITY AND METHODS OF THEIR APPLICATION | |
| RU2008917C1 (en) | Method for purulent wounds treatment | |
| RU2083207C1 (en) | Method of treatment of experimental glanders in golden hamsters | |
| SU1629062A1 (en) | Method for treatment of calves with colibacillosis |